The Medical Letter on Drugs and Therapeutics
				
			FROM
ISSUE 1658
    
   			ISSUE 1658
September 5, 2022
                			
                		 Issue 1658
                		- Prevention and Treatment of Monkeypox
 - Baricitinib (Olumiant) for Severe Alopecia Areata
 - Nalmefene Returns for Reversal of Opioid Overdose
 - Upadacitinib (Rinvoq): A Second JAK Inhibitor for Ulcerative Colitis
 - A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)
 - In Brief: Edaravone Oral Suspension (Radicava ORS) for ALS (online only)
 
					Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
				
				Prevention and Treatment of Monkeypox
September 5, 2022 (Issue: 1658)
				An outbreak of monkeypox has recently spread around
the globe and across the US. Updated information
about the current outbreak is available from the CDC.
        			
        			
					
					
				
        			
				The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
				